ORPHA:96167
Recombinant 8 syndrome
Also known as: Duplication 8q/deletion 8p · Rec(8) syndrome · Rec8 syndrome · Recombinant chromosome 8 syndrome · San Luis Valley syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
35
30.9th percentile
Trials
0
Interventional, condition-specific
Researchers
207
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Recombinant 8 (rec(8)) syndrome, also known as San Luis Valley syndrome, is a complex chromosomal disorder that is due to a parental pericentric inversion of chromosome 8 and is characterized by major heart anomalies, urogenital malformations, moderate to severe intellectual deficiency and mild craniofacial dysmorphism.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008365
- MeSH:C535296
- OMIM:179613
- UMLS:C0795822
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
35 matched papers (13 in last 10 years) Source
- Phenotype characterisedPresent
91 HPO annotations (e.g. Delayed CNS myelination; Postnatal growth retardation; Downturned corners of mouth) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
91
Associated phenotypes · MONDO:0008365
- Delayed CNS myelination
- Postnatal growth retardation
- Downturned corners of mouth
- Global developmental delay
- Malar flattening
Showing 5 of 91 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
35
35 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
35 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
13 in the last 10 years · high confidence · 30.9th percentile (publications denominator)
Phrase hits: 35 · MeSH hits: 0
Who's working on it?
207
Distinct author names in 35 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01
- 02
- 03Clericuzio C2 papers · 2019
Department of Pediatrics University of New Mexico Albuquerque New Mexico.
Papers in Europe PMC - 04Cortelli JR2 papers · 1999Papers in Europe PMC
- 05Graw SL2 papers · 2002
Eleanor Roosevelt Institute, Denver, CO, 80206, USA. sgraw@eri.uchsc. edu
Papers in Europe PMC - 06Hart TC2 papers · 1999
Department of Pediatrics, Section on Medical Genetics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. thart@bgsm.edu
Papers in Europe PMC - 07Helm BM2 papers · 2022
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Papers in Europe PMC - 08Landis BJ2 papers · 2022
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Papers in Europe PMC - 09McConnell TS2 papers · 1991Papers in Europe PMC
- 10Pallos D2 papers · 1999Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN16119881·No longer recruiting·Clinical observation of Yishen Jiangzhuo therapy in the treatment of non-dialysis renal anemia patients with stage 3–4 chronic kidney disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72157798·Recruiting·Developing a vaccine against Bundibugyo ebolavirus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66014475·Recruiting·European preparedness platform to treat and prevent respiratory syncytial virus infections in pregnant women and infants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65235904·Recruiting·A study to learn how the study medicine called PF-07868489 is tolerated and acts in people with pulmonary arterial hypertension
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30482473·No longer recruiting·A Phase II study to understand the safety and effects of inhaled SNG001, the study medication, in patients who are mechanically ventilated due to a respiratory viral infection in the lungs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14012649·Recruiting·PRX-102 in children and adolescents with Fabry disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN92114384·Recruiting·PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHESY-2 trial)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45965456·Suspended·Randomised, open-label international trial with Verapamil alone compared with Verapamil plus another immunotherapy for people with newly diagnosed type 1 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36032472·No longer recruiting·Evaluation of the safety of ovarian support cell in vitro maturation (OSC-IVM) application during in vitro fertilization procedures for infertility treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10454031·No longer recruiting·A clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26495549·No longer recruiting·Combining recombinant herpes zoster and influenza or COVID-19 vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15170461·Stopped·A first in human subjects clinical trial of a bioactive dressing designed to reduce scarring of skin burns
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20835488·No longer recruiting·Effect of premixed insulin combined with mulberry twig alkaloids tablet or metformin on blood glucose fluctuation in type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12022293·No longer recruiting·Evaluating the persistence of protection of a 3rd dose of COVID vaccine and the safety and induced protection of a 4th dose of COVID-19 vaccines in previously vaccinated adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79243381·No longer recruiting·Investigating a vaccine against plague in Uganda (PlaVac Uganda)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13649456·No longer recruiting·A study of three malaria vaccines to prevent the transmission of malaria in adults in Mali: TBVax2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59409907·No longer recruiting·A study to compare how the body processes first and second generation RO7490677 (recombinant human pentraxin-2; rhPTX-2) drug products in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30808508·No longer recruiting·A comparison of response to treatment in patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes taking ASTX727 versus best supportive care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16171129·No longer recruiting·A randomised Phase II trial to assess whether niraparib is beneficial in patients with mesothelioma that has progressed and been previously treated when compared to the standard of care treatment, termed active symptom control
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26168155·No longer recruiting·Study evaluating the safety and activity of cevostamab (BFCR4350A) given by subcutaneous injection in participants with relapsed or refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41077863·No longer recruiting·Investigating a vaccine against plague
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14391248·No longer recruiting·Combining influenza and COVID-19 vaccination (ComFluCOV) study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11093445·No longer recruiting·A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55659103·No longer recruiting·Dydrogesterone or micronized progesterone related birth defects in children
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Recombinant 8 syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Recombinant 8 syndrome" OR "Duplication 8q/deletion 8p" OR "Rec(8) syndrome" OR "Rec8 syndrome" OR "Recombinant chromosome 8 syndrome" OR "San Luis Valley syndrome"
MeSH descriptor terms unioned into the query: Recombinant chromosome 8 syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Recombinant 8 syndrome" OR "Duplication 8q/deletion 8p" OR "Rec(8) syndrome" OR "Rec8 syndrome" OR "Recombinant chromosome 8 syndrome" OR "San Luis Valley syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T04:55:25.837Z
